The Lancet Haematology launched in Autumn 2014, joining the growing collection of Lancet specialty journals. As an exclusively online journal, this new monthly title is dedicated to publishing original research that advocates change in, or illuminates, haematological clinical practice.
…
continue reading
Lan-Lan Smith, Editor-in-Chief, and Emma Cookson, Senior Editor at The Lancet Haematology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy. A monthly audio companion to the journal, this podcast covers a broad range of topics, from racial and ethnic disparities in leukaemia survival outcomes to resuscitation with blood products compared with saline, the link between mental health and lymphoma to haemol ...
…
continue reading
Welcome to Basics to Brilliance, the Haematology podcast created to supplement & bolster your knowledge for the FRCPath Part 1. Featuring a two way, non-didactic conversational-style Q&A between the SpR and SHO, this podcast will be your pocket companion no matter where you are. We aim to cover: - Malignant and non-malignant topics - The whole syllabus for FRCPath part 1 - Review UK guidelines - Go into science/lab detail - Discuss how guidelines often translate into practice - Review and ap ...
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Matteo Della Porta on the phase 3 COMMANDS trial examining luspatercept versus epoetin alfa in patients with lower-risk myleodysplastic syndrome
8:08
8:08
Play later
Play later
Lists
Like
Liked
8:08
Professor Matteo Giovanni Della Porta joins us to discuss the primary analysis of the phase 3 COMMANDS trial comparing luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndrome patients. Continue this conversation on social! Follow us today at... https://twitter.com/thelan…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
In conversation with... Matteo Giovanni Della Porta
8:08
8:08
Play later
Play later
Lists
Like
Liked
8:08
Professor Matteo Giovanni Della Porta joins us to discuss the primary analysis of the phase 3 COMMANDS trial comparing luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndrome patients.By The Lancet
…
continue reading
Dr Kim Linton joins us to discuss the EPCORE NHL-1 trial testing monotherapy with the bispecific antibody epcoritamab for patients with relapsed or refractory follicular lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00166-2?dgcid=buzzsprout_tlv_podcast_generic_lanhae Continue this conversation o…
…
continue reading
Dr Kim Linton joins us to discuss the EPCORE NHL-1 trial testing monotherapy with the bispecific antibody epcoritamab for patients with relapsed or refractory follicular lymphoma.By The Lancet
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Judy Truong on ferritin reference levels and iron deficiency
11:17
11:17
Play later
Play later
Lists
Like
Liked
11:17
Dr Judy Truong join us to discuss ferritin reference intervals and how adoption of evidence-based ferritin clinical decision limits can help clinicians detect and treat iron deficiency, minimising propagation of related health inequity and social injustice in medicine. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS235…
…
continue reading
Dr Judy Truong join us to discuss ferritin reference intervals and how adoption of evidence-based ferritin clinical decision limits can help clinicians detect and treat iron deficiency, minimising propagation of related health inequity and social injustice in medicine.By The Lancet
…
continue reading
![Artwork](/static/images/128pixel.png)
1
In conversation with... Johannes Schetelig
14:11
14:11
Play later
Play later
Lists
Like
Liked
14:11
Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia.By The Lancet
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML
14:11
14:11
Play later
Play later
Lists
Like
Liked
14:11
Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00065…
…
continue reading
Polycythaemia- red cell # Erythrocytosis – in red cell mass Absolute Erythrocytosis - M: Hct >0.60 or >0.52 + RCM >25% of mean - F: Hct >0.56 or >0.48 + RCM >25% of mean Apparent Erythrocytosis - Men: Hct >0.52 + normal RCM - Women: Hct >0.48 + normal RCM Relative erythrocytosis -Normal RCM + Reduced plasma volume (pathological dehydration) M>F Med…
…
continue reading
Professor Banu Aygun joins us to discuss the REACH trial testing hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00078-4?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us toda…
…
continue reading
Professor Banu Aygun joins us to discuss the REACH trial testing hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa.By The Lancet
…
continue reading
- Synchronous CNS and systemic lymphoma at initial presentation (treatment-naïve; TN-SCNSL) - CNS relapse without recurrent systemic lymphoma (relapsed isolated CNS lymphoma; RI-SCNSL) - Relapsed concomitant systemic and CNS disease following treatment for systemic lymphoma (RC-SCNSL) Generally hybrid disease Investigations - MRI Head w gadolinium …
…
continue reading
CNS Lymphomas 1% of all NHL 3% of all Brain tumours Most common subtype (90%) is DLBCL Clinical division: 1. 1* CNS lymphoma, 2. 2* CNS lymphoma - TN-SCNSL - RI-SCNSL - RC-SCNSL 3. Immune deficiency assoc- HIV; better prog. Presentation: - SOL Sx - Raised ICP: morning headaches w N+V - Neuropsych, Behavioural, Memory, Language - Focal motor + Strok…
…
continue reading
Chronic MyeloMonocytic Leukemia (not CML) Persistently high monocyte count- 3 months Most frequent MDS/Myeloproliferative neoplasms – a cross between the two Median age 72 Median survival 20-40 months Transformation to AML (15-30%) WHO definition of CMML: 1. Excess monocytes- persistent over 3 months, ≥ 1 - Monocytes 10% of total WC count 2. Dyspla…
…
continue reading
Chronic Lymphocytic Leukemia (CLL)- Chronic Relapsing Remitting Most common leukemia in adults Incurable but treatable *Remember Supportive Care* Median age of 72 M > F 80% incidental SLL: lymphocytes in lymph nodes and spleen instead of blood Presentation: 1) Fatigue 2) B symptoms 3) High WC 4) Cytopenias (Marrow infiltrate, AIHA, ITP, Hyposplenis…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
In conversation with... Sabine Braat and Katherine Fielding
18:06
18:06
Play later
Play later
Lists
Like
Liked
18:06
Dr Sabine Braat and Dr Katherine Fielding join us to discuss their study presenting new haemoglobin thresholds for defining anaemia.By The Lancet
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Sabine Braat and Katherine Fielding on haemoglobin thresholds to define anaemia
18:06
18:06
Play later
Play later
Lists
Like
Liked
18:06
Dr Sabine Braat and Dr Katherine Fielding join us to discuss their study presenting new haemoglobin thresholds for defining anaemia. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00030-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us today at... https:…
…
continue reading
Doctor Elisabeth Schorb joins us to discuss the MARTA phase 2 trial, treating older, fit patients with primary diffuse large B-cell CNS lymphoma with high-dose chemotherapy and autologous stem-cell transplantation. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00371-X/fulltext?dgcid=buzzsprout_icw_podcast…
…
continue reading
Doctor Elisabeth Schorb joins us to discuss the MARTA phase 2 trial, treating older, fit patients with primary diffuse large B-cell CNS lymphoma with high-dose chemotherapy and autologous stem-cell transplantation.By The Lancet
…
continue reading
Professor Stephan Ehl joins us to discuss a prospective observational study on paediatric autoimmune lymphoproliferative immunodeficiencies.By The Lancet
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Stephan Ehl on paediatric autoimmune lymphoproliferative immunodeficiencies
13:03
13:03
Play later
Play later
Lists
Like
Liked
13:03
Professor Stephan Ehl joins us to discuss a prospective observational study on paediatric autoimmune lymphoproliferative immunodeficiencies. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00638-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Continue this conversation on social! Follow us today at..…
…
continue reading
Dr Sarah O'Brien joins Lan-Lan Smith to discuss results of the phase 3 PREVAPIX-ALL trial, which compares direct oral anticoagulant apixaban to low-molecular-weight-heparin for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma.By The Lancet
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Dr Sarah O'Brien on the PREVAPIX-ALL trial
13:50
13:50
Play later
Play later
Lists
Like
Liked
13:50
Dr Sarah O'Brien joins Lan-Lan Smith to discuss results of the phase 3 PREVAPIX-ALL trial, which compares direct oral anticoagulant apixaban to low-molecular-weight-heparin for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma. Read the full article: https://www.thelancet.com/journal…
…
continue reading
Professor Enrico Lopriore joins us to discuss a trial testing darbepoetin alfa to prevent postnatal anaemia in infants with haemolytic disease of the fetus and newborn.By The Lancet
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Enrico Lopriore on haemolytic disease of the fetus and newborn
12:33
12:33
Play later
Play later
Lists
Like
Liked
12:33
Professor Enrico Lopriore joins us to discuss a trial testing darbepoetin alfa to prevent postnatal anaemia in infants with haemolytic disease of the fetus and newborn. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00285-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on …
…
continue reading
Professor Meletios Dimopoulos joins us to discuss two trials for patients with relapsed and refractory multiple myeloma - the first report of the DREAMM-3 phase 3 and long-term follow-up of the APOLLO phase 3 trial.By The Lancet
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Meletios Dimopoulos on relapsed and refractory multiple myeloma
11:00
11:00
Play later
Play later
Lists
Like
Liked
11:00
Professor Meletios Dimopoulos joins us to discuss two trials for patients with relapsed and refractory multiple myeloma - the first report of the DREAMM-3 phase 3 and long-term follow-up of the APOLLO phase 3 trial. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00243-0/fulltext?dgcid=buzzsprout_icw_podcas…
…
continue reading
Dr Eric Ohuma joins us to tell us about a study recently published in The Lancet Haematology on the association between maternal haemoglobin concentrations and maternal and neonatal outcomes.By The Lancet
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Eric Ohuma on haemoglobin concentrations and neonatal outcomes
16:27
16:27
Play later
Play later
Lists
Like
Liked
16:27
Dr Eric Ohuma joins us to tell us about a study recently published in The Lancet Haematology on the association between maternal haemoglobin concentrations and maternal and neonatal outcomes. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00170-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continu…
…
continue reading
Professor Margaret Ragni joins us to discuss the VWDMin study, published in The Lancet Haematology. In this phase 3, randomised, crossover trial, recombinant von Willebrand factor and tranexamic acid are used to treat heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA.…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Margaret Ragni on tranexamic acid to treat heavy menstrual bleeding
13:13
13:13
Play later
Play later
Lists
Like
Liked
13:13
Professor Margaret Ragni joins us to discuss the VWDMin study, published in The Lancet Haematology. In this phase 3, randomised, crossover trial, recombinant von Willebrand factor and tranexamic acid are used to treat heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA. Read the full article: https://www.th…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
In conversation with... Oreofe Odejide and Thomas Kuczmarski
16:32
16:32
Play later
Play later
Lists
Like
Liked
16:32
Dr Odejide and Dr Kuczmarski tell us about a study recently published in The Lancet Haematology on the effect of pre-existing mental health conditions on survival in patients with diffuse large B-cell lymphoma.By The Lancet
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Oreofe Odejide and Thomas Kuczmarski on mental health and lymphoma
16:32
16:32
Play later
Play later
Lists
Like
Liked
16:32
Dr Odejide and Dr Kuczmarski tell us about a study recently published in The Lancet Haematology on the effect of pre-existing mental health conditions on survival in patients with diffuse large B-cell lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00094-7/fulltext?dgcid=buzzsprout_icw_podcast_gen…
…
continue reading
Professor Alok Srivastava tells us about two clinical trials being published in The Lancet and The Lancet Haematology on a new siRNA therapy called fitusiran for patients with haemophilia A and B.By The Lancet
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Alok Srivastava on fitusiran for patients with haemophilia A and B
18:41
18:41
Play later
Play later
Lists
Like
Liked
18:41
Professor Alok Srivastava tells us about two clinical trials being published in The Lancet and The Lancet Haematology on a new siRNA therapy called fitusiran for patients with haemophilia A and B. Read the two trials: Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH) https://www.t…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Emmanuela E Ambrose on stroke prevention in children with sickle cell disease
11:31
11:31
Play later
Play later
Lists
Like
Liked
11:31
Dr Emmanuela E Ambrose tells us about the SPHERE trial on hydroxyurea dose escalation for primary stroke prevention in children with sickle cell disease in Tanzania Read the full article: Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE) Continue this conversation on social!…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
In conversation with... Emmanuela E Ambrose
11:31
11:31
Play later
Play later
Lists
Like
Liked
11:31
Dr Emmanuela E Ambrose tells us about the SPHERE trial on hydroxyurea dose escalation for primary stroke prevention in children with sickle cell disease in TanzaniaBy The Lancet
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Sumit Gupta on racial and ethnic disparities in leukaemia survival outcomes
22:10
22:10
Play later
Play later
Lists
Like
Liked
22:10
Dr Sumit Gupta discusses how racial and ethnic disparities affect survival outcomes of children and young adults with acute lymphocytic leukaemia. Read the full article: Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia Continue this conversation on social! Follow us today at... https://twitter.com/thelancet htt…
…
continue reading
Dr Sumit Gupta discusses how racial and ethnic disparities affect survival outcomes of children and young adults with acute lymphocytic leukaemia.By The Lancet
…
continue reading
Professor Xiao-Jun Huang discusses this Lancet Haematology series on Cellular Therapy in China, covering the history, current research challenges, and future of HSCT and CAR T-cell therapies in China.By The Lancet
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Xiao-Jun Huang on cellular therapy in China
28:10
28:10
Play later
Play later
Lists
Like
Liked
28:10
Professor Xiao-Jun Huang discusses this Lancet Haematology series on Cellular Therapy in China, covering the history, current research challenges, and future of HSCT and CAR T-cell therapies in China. Read the Series papers: Cellular therapy in China Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://i…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Glenn Pierce on haemophilia care in LMICs
34:55
34:55
Play later
Play later
Lists
Like
Liked
34:55
Dr Glenn Pierce discusses the World Federation of Hemophilia’s Humanitarian Aid Program which provides access to haemophilia care in low-income and lower-middle-income countries. Read the full Review: Achieving access to haemophilia care in low-income and lower-middle-income countries Continue this conversation on social! Follow us today at... http…
…
continue reading
Dr Glenn Pierce discusses the World Federation of Hemophilia’s Humanitarian Aid Program which provides access to haemophilia care in low-income and lower-middle-income countries.By The Lancet
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Amy DeZern on the link between myelodysplastic syndrome and autoimmune disorders
12:50
12:50
Play later
Play later
Lists
Like
Liked
12:50
Dr Amy DeZern discusses the link between myelodysplastic syndrome and autoimmune disorders and the need for a multidisciplinary approach for the treatment of patients who have both. Read the full article: Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin? Continue this conversation on social! Follow us today at... https:…
…
continue reading
Dr Amy DeZern discusses the link between myelodysplastic syndrome and autoimmune disorders and the need for a multidisciplinary approach for the treatment of patients who have both.By The Lancet
…
continue reading
![Artwork](/static/images/128pixel.png)
1
In conversation with... Nicholas Crombie and Gavin Perkins
15:05
15:05
Play later
Play later
Lists
Like
Liked
15:05
Dr Nicholas Crombie and Professor Gavin Perkins discuss their randomised phase 3 trial in which they investigated resuscitation with blood products compared with saline in patients with trauma-related haemorrhagic shock receiving prehospital care.By The Lancet
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Nicholas Crombie and Gavin Perkins on resuscitation with blood products compared with saline
15:05
15:05
Play later
Play later
Lists
Like
Liked
15:05
Dr Nicholas Crombie and Professor Gavin Perkins discuss their randomised phase 3 trial in which they investigated resuscitation with blood products compared with saline in patients with trauma-related haemorrhagic shock receiving prehospital care. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://inst…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
In conversation with... Fredrik Schjesvold
12:24
12:24
Play later
Play later
Lists
Like
Liked
12:24
Dr Fredrik Schjesvold discusses the results of the OCEAN phase 3 trial testing melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide.By The Lancet
…
continue reading
Dr Fredrik Schjesvold discusses the results of the OCEAN phase 3 trial testing melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide. Read the full article: Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN) Continue this conversatio…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Jacob D Soumerai and Andrew D Zelenetz on the BOVen regimen for previously untreated patients with chronic lymphocytic leukaemia
11:59
11:59
Play later
Play later
Lists
Like
Liked
11:59
Dr Jacob D Soumerai and Prof Andrew D Zelenetz discuss their phase 2 trial of the BOVen regimen and MRD-driven treatment discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00307-0/fulltext Continu…
…
continue reading